Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the captcha-bank domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home1/c306474/public_html/wp-includes/functions.php on line 6131
Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the email-users domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home1/c306474/public_html/wp-includes/functions.php on line 6131
Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home1/c306474/public_html/wp-includes/functions.php on line 6131 tuberculosis Archives - TalkAfrique Deprecated: Function WP_Dependencies->add_data() was called with an argument that is deprecated since version 6.9.0! IE conditional comments are ignored by all supported browsers. in /home1/c306474/public_html/wp-includes/functions.php on line 6131
Deprecated: Function WP_Dependencies->add_data() was called with an argument that is deprecated since version 6.9.0! IE conditional comments are ignored by all supported browsers. in /home1/c306474/public_html/wp-includes/functions.php on line 6131
In the past, the two diseases dominated any healthcare conversation when the subject was about Africa. Times have changed. Today, diabetes, cancer, and heart and respiratory diseases are emerging as the top killers in Africa. Though infectious diseases remain a threat, the trendline is changing due to the rise of non communicable diseases (NCD). These used to be called the diseases of the rich but urbanization, smoking and the intrusion of western diets have broken the insulation African used to enjoy against these diseases. What is alarming is that African healthcare infrastructure are not currently able to manage these non communicable diseases.
In the weeks ahead, I will be delving into the issues of non-communicable diseases in Africa, the case for more funding of research to understand the rise NCDs and what governments need to do to avoid NCDs becoming the next malaria and TB.
Mr Bill Gates: co-chair of the Bill & Melinda Gates Foundation
Mr. President, Prime Minister Sheikh Hasina, Director-General Dr. Margaret Chan, Excellencies, ladies and gentlemen.
The World Health Organization and this assembly have set the standard for global cooperation in pursuit of better health. For decades, you have established ambitious goals, such as eradicating smallpox. And you have rallied the world to accomplish those goals. It is an honor to join you today.
I had the privilege of addressing this assembly in 2005, when my wife Melinda and I were new to global health. At that time, we were so optimistic about the future. The world was finally starting to use its greatest resource, innovation, to solve this difficult problem – the fact that billions of people don’t have the chance to lead a healthy, productive life.
In the past six years, my optimism has continued to grow.
An recent important new book Getting Better by the economist Charles Kenny shows that life is getting better, rapidly, for people in poor countries. To build his argument, he examines a series of key quality-of-life indicators, including child survival, school enrollment, and levels of violence.
I hope this book gets the acclaim it deserves. It proves that the great work this assembly has been leading is having an enormous impact. We need the people who make funding decisions and set policy to understand the progress being achieved every day. I believe we have the opportunity to make even more progress, faster, for more people.
This opportunity is the reason I devoted my time to the Gates Foundation. Health and development is the most rewarding work I can think of, and Melinda and I will devote the rest of our lives to it.
When I was a teenager, I was captivated by computers because I believed they would change the world. I couldn’t predict exactly what the future would look like, but I was amazed by a sense to improve and empower.
Over the years, as I watched so much change taking root, I also saw glimpses of what was not changing. In 1994, I traveled to sub-Saharan Africa. It was impossible to ignore the devastating impact of disease and poverty on people’s lives.
Then, in 1998, Melinda and I read an article about rotavirus. We learned that it was the leading cause of diarrhea in young children – and that it caused 500 000 deaths annually. Our first child had just been born, and there was a good chance she’d suffered from rotavirus. But in the United States, children don’t die from diarrhea, so this was not a worry for us.
We’d never been forced to reckon with rotavirus, in fact, we’d never even heard of it because there was no chance our daughter would be killed by it.
This was a sobering realization for me. I had built my life around the idea that innovation is for everyone. When I began to understand how billions of people are deprived of its benefits, it made me angry. That’s when I decided to use my personal wealth would be used to help confront that inequity.
Thirty years ago, when I founded Microsoft my colleagues and I envisioned a computer for everyone. Now, I join you in seeking good health care for every human being.
At the Gates Foundation, our goal is to spur innovation on health problems.
Our priorities are your priorities: to make motherhood safer; to ensure that newborns survive their first 30 days; to provide children with a nutritious diet.
We see what you see everyday – that diseases like HIV, tuberculosis, and malaria can destroy communities. Along with great partners like the Global Fund, we want to help you diagnose, treat, and above all, prevent disease.
As we think about how to deploy our resources most effectively, one intervention stands out: vaccines.
Today, I would like to talk about how you can provide the leadership to make this the Decade of Vaccines.
Vaccines are an extremely elegant technology. They can be inexpensive, they are easy to deliver, and they are proven to protect children lifelong from disease. At Microsoft, we dreamed about technologies that were so powerful and yet so simple. Today, I like to imagine what the future will look like when world leaders start to take full advantage of vaccines.
In this Decade, we can achieve a lot.
Early in this decade, we will eradicate polio.
By the end of the decade, five or six new vaccines will be available to all children of the world.
And, crucially, every country in the world will have built a delivery system made to get vaccines to every last child.
To put an end to polio and reach all children with new vaccines, we must create strong immunization programmes.
In January of last year, I called for the world to accelerate progress on vaccines. That was a moment, and now there is momentum. I’m excited that global health leaders are now collaborating to put a specific global vaccine action plan in place.
The success of that plan will be a blueprint for the success of the Decade of Vaccines. It will depend on us to do our best work.
Vaccines and immunization
The greatest asset of every country is the energy and talent of its people. Disease saps that energy and squanders that talent. Repeated intestinal infections stunt children’s growth and reduce their cognitive development. Meningitis can cause permanent neurologic disability. Malaria prevents people from being productive; over a lifetime, high rates of malaria are cause substantially reduced earnings.
That’s why vaccines are one of the best investments we can make in the future: healthy people drive thriving economies. As we free billions of people from the relentless burden of sickness and death will unleash more human potential than ever before.
Let me give you an example of the difference vaccines can make.
This year, 20 million children will have severe pneumonia. More than a million will die. But even when the disease doesn’t take a child’s life, it can affect the child’s and family’s future.
For the survivors, the sickness reduces their chances of growing up healthy and strong. Their parents will go into debt. But we now have vaccines against two of the leading causes of pneumonia which make it possible for countries to reduce the burden and tap into people’s energy and nurture their talent.
Product development
The pneumonia vaccines are a symbol of one of the most exciting trends in global health, the drive towards equity in delivering innovations.
In the past, innovations developed vaccines for rich countries, and it took more than a decade before they were introduced in poor countries. But that is changing.
The newest pneumonia vaccines were available in developing countries only a few years after they were approved for use in developed countries. The same is true of a new rotavirus vaccine. But approved and available don’t mean delivered. Now it is up to the GAVI Alliance and many of you in this room to ensure that these vaccines reach the children who need them.
Last December, Burkina Faso, Mali, and Niger made history when they introduced a brand new vaccine for Meningitis A, the first vaccine developed specifically for use in Africa.
The story began in 1996, when the deadliest meningitis epidemic in memory tore through 25 countries in Africa, infecting more than 250 000 people. Meningitis strikes with frightening speed. A perfectly healthy child can be playing with friends one minute and literally be dead a few hours later.
In 1996, the only weapon against meningitis was barely useful at all, a short-lasting vaccine that wasn’t effective among young children. Health officials used it to control outbreaks that were already raging, so they called it “medicine after death.” They demanded a better vaccine that could prevent outbreaks.
The WHO and an organization called PATH formed the Meningitis Vaccine Project in 2001. The partners set a target price of 50 cents for the vaccine, which would make it affordable.
But producing a vaccine at that low price required a new approach to drug development. The Meningitis Vaccine Project worked with a Dutch biotech company to obtain key raw materials and arranged a technology transfer from the United States. Then, the Serum Institute of India agreed to manufacture the vaccine at the target price.
I am pleased to announce that we now have very early results from the use of vaccines from Burkina Faso. In the first 16 weeks of this year, there was just a single case of meningitis reported in the country.
It’s too soon to declare victory, but the early data makes me hopeful. For centuries, meningitis terrorized a region of 400 million people. This vaccine can help end the terror.
We need to continue creating and delivering more vaccines, but finally, for the first time, we can see a bright future.
Vaccine coverage
To keep the promise of equitable access to health care, all new vaccines must be priced low enough so that all countries can afford them. The Gates Foundation is working with many vaccine manufacturers to ensure that vaccines are available at a reasonable price. I believe that we can cut the combined price of the pentavalent, pneumococcus, and rotavirus vaccines in half by 2016.
But even when prices are fair, delivering vaccines to every child takes a great commitment.
Many developing countries are already doing a great job. Bangladesh, Nicaragua, Rwanda, and Vietnam routinely reach about 90 percent of their infants. But there are many places where vaccination rates are low. Almost every country can do better, must do better, if this decade is to reach the potential of the Decade of Vaccines.
Leading a health ministry is a hard job. You face a multitude of complicated choices. The stakes are always life and death and you have many priorities.
But you all have access to one key resource: your own leadership. And leadership can be decisive. The best immunization systems work because leaders hold themselves accountable for results. They diagnose problems, innovate to solve them, and spread the best ideas.
Let me give an example. Just a few years ago, the Indian state of Bihar was vaccinating under 30 percent. Then, a new chief minister, Nitish Kumar, was elected, and he made it clear that he expected change.
So even though Bihar is still one of the most challenging places in the world, but it’s no longer one of the least vaccinated. Under Chief Minister Kumar, the vaccination rate has more than doubled, and it plans to go higher.
I visited with Chief Minister Kumar two months ago, and his understanding of what was working and what wasn’t was impressive. He understood the innovations that were being tested.
Examples like this inspire all of us for better leadership. I was also struck by the chief minister’s popularity. People are hungry for visionary leaders who not only promise a better future, but take a basic system and make it work.
Today, I ask for your leadership. In 2005, you set two critically important immunization-related goals that we have not yet reached.
Let us renew our pledge that no country will be below 90 percent coverage. Let us rededicate ourselves to the idea that no district will be below 80 percent coverage. We will meet those goals if, and only if, you lead. With your leadership, you will make this the Decade of Vaccines.
As a global health community, it is imperative that we shine a light on the countries doing the best work. We need to know who the innovators are, so that the most powerful ideas spread far and wide.
Starting in 2012, the Gates Foundation will bestow an award on the individual or organization that has made the most uniquely innovative contribution to the Decade of Vaccines. This could be innovation in the science, delivery, or funding of vaccines. I will announce the winner every January in my annual letter. My goal is to make sure that pioneering global health leaders get the credit they deserve.
Polio
The long fight against polio proves just how powerful vaccine technology can be, but it also demonstrates that it is only as effective as the quality of delivery.
Twenty-three years ago, here in this building, the delegates to this Assembly resolved to wipe polio off the planet. And now we’re 99 percent of the way there, because of two things: a 13 cent vaccine so easy to administer that even I have done it many times; and the most impressive, farthest-reaching delivery effort global health has ever seen.
It is fantastic that more than 100 countries no longer have polio. In the most difficult conditions in the world, we are making stunning progress. Despite the ongoing war, Afghanistan has had only one case this year.
But progress is not the same as success, and eradication is not guaranteed. We have tools: diagnostics, surveillance systems, and vaccines that are constantly being improved, but the virus keeps spreading back into countries where it had been eliminated. There are countries where the virus continues to circulate, despite multiple campaigns every year. Globally, the polio programme is not assured of funding to keep running campaigns and improving vaccination systems.
These discouraging facts raise a question: do we really have the political commitment to eradicate polio?
Are donor countries, especially the G8, ready to close today’s funding gap and see the job through to the very end?
Are the countries where polio still exists ready to take extraordinary action to reach every single child with the vaccine?
We have a choice. We can keep doing what we’ve been doing, immunizing the same children over and over and missing the children who are the most vulnerable. Or we can do more. We can step up our fundraising, we can intensify our campaigns, and we can do what it takes to get to zero cases. If we make that choice, we will prove that people are capable of coming together to solve complex, worldwide problems.
The eradication of polio will be a great victory for this Assembly. You started the courageous fight against this disease. You will finish it. And then you will be able to move on to the next ambitious goal.
One of the polio leaders I respect most is Dr. Muhammad Pate, who directs Nigeria’s national eradication effort. Just a few years ago, Nigeria was the most troublesome spot on the polio map. It had hundreds of cases. Much worse, it lacked the commitment to bringing that number down.
But Dr. Pate, along with the global polio partners, President Goodluck Jonathan, and members of the ministry of health, helped rally government and traditional leaders around the cause. Dr. Pate told me that his agency makes a point of identifying poor-performing states publicly. That’s the kind of accountability that leads to results. Last year, thanks to a nationwide effort, polio was down 95 percent in Nigeria. Nigeria’s leaders still have a lot of work ahead of them, but they have turned the polio programme around.
During my last visit to Nigeria, Dr. Pate asked me a small favor. He hoped I’d be willing to sign his daughter’s school yearbook. I was more than willing, of course, and I want Dr. Pate’s daughter to know this: I admire her father very much, I want to someday introduce my children to him one day soon, and I hope more than anything that when that day comes we shall be celebrating the fact that there is no more polio in Nigeria.
Call to action
The world has a great opportunity right now, and whether or not we seize it will depend in large part on those of us in this room. It will depend on our ability to do the difficult, necessary things to usher in the Decade of Vaccines.
Donor countries, will have to increase investment in vaccines and immunization, even though they are coping with budget crises. The GAVI Pledging meeting in June gives you and your governments the opportunity to show your support. If donors are generous, we will prevent 4 million deaths by 2015. By 2020, we can prevent 10 million deaths.
Pharmaceutical companies, you must make sure vaccines are affordable for poor countries. Specifically, you must make a commitment to tiered pricing.
For all 193 Member States, you must make vaccines a high priority focus of your health systems, to ensure that all your children have access to existing vaccines now, and to new ones that have recently become available.
At the Gates Foundation, we are committed to working with all our partners – civil society, donors, drug companies, and national governments – to help you do the difficult but necessary things.
I am confident because I’ve seen so many examples of leadership.
British Prime Minister David Cameron passed the toughest austerity budget in his country’s memory. Yet, in the face of enormous pressure, he kept his promise to maintain development spending. A few months later, he announced that the United Kingdom would double its commitment to the polio campaign.
Another example is the Serum Institute of India, led by Dr. Cyrus Poonawalla, has broken the mold for the low-cost manufacture of vaccines. They developed the meningitis vaccine, they are the world’s largest producer of the measles vaccines, and they provide the pentavalent vaccine to GAVI at a lower price than any other manufacturer in the world. In the coming years they will manufacture inexpensive diarrhea and pneumonia vaccines.
Nitish Kumar and Muhammad Pate and many others have demonstrated that the best leaders can overcome tough challenges.
Together, and with your leadership, we can make this the decade in which we take full advantage of the technology of vaccines. When we do it, we will build an entirely new future based on the understanding that global health is the cornerstone of global prosperity.
It might be the most difficult thing we’ve ever done, but it will also be the most important.
Global health experts said on Thursday that the world’s most powerful drugs are losing the battle against drug-resistant strains of malaria, HIV, gonorrhea and tuberculosis
According to Dr. Thomas Frieden, director of the Centers for Disease Control and Prevention, antimicrobial resistance is robbing us of the certainty that antibiotics will always be there to fight infections and new drug-resistant pathogens are emerging. “It’s not enough to hope that we’ll have effective drugs to combat these infections. We must all act now to safeguard this important resource,” Frieden said
What you need to know about Anti-Microbial Resistance
What is Anti-Microbial Resistance:
Antimicrobial resistance occurs when germs change in a way that reduces or eliminates the effectiveness of drugs to treat them. This happens when antibiotics, antivirals, antifungals and other medications are used too liberally. About half of antimicrobial drugs — antibiotics in particular — are used unnecessarily or inappropriately prescribed in U.S. hospitals and in doctors’ offices, the CDC says. The best approach to preserving those drugs is to use them only when needed.
How Anti-Microbial Resistance affects developing world, especially Africa
HIV: Studies show that up to 20 percent of newly diagnosed HIV patients have transmitted a drug-resistant infection. Approximately 22 million people live with HIV in Sub-Saharan Africa. In the US and other developed countries, Doctors can test or resistance before prescribing drugs, but such luxury may be too hard to come by in under-privileged communities
Malaria: Plasmodium falciparum, the most dangerous of the malaria parasites, has developed resistance in nearly all areas of the world where it is transmitted. Annually, there are about 225 million malaria infections and nearly 800,000 deaths. Women and children are the most affected, particularly in Sub-Saharan Africa.
Joanne Carter
Executive director of RESULTS/RESULTS Educational Fund (REF)
Last week Congress approved a two-week extension of federal funding to avoid a looming government shutdown. The vote postpones — but does not resolve — potentially devastating cuts to global health programs. The House-proposed bill for the balance of 2011 proposes deep cuts to some of the most effective investments the US makes globally, including a drastic 40 percent reduction for the Global Fund to Fight AIDS, Tuberculosis and Malaria.
In a recent interview Michael Gerson, a former speechwriter and advisor to President George W. Bush, called the cuts “irrelevant and destructive.” He’s right on both counts, and there’s still time for Congress to reverse course.
The cuts are irrelevant to the deficit problem that members of Congress are ostensibly trying to solve. Our entire foreign aid portfolio amounts to little more than a rounding error in the federal budget. Foreign aid focused on health, education, economic opportunity, and other anti-poverty programs account for less than 1 percent of federal spending. Even if Americans believed that erasing these programs was a good idea — and they don’t, as public opinion polls consistently reveal — it wouldn’t put a dent in the deficit.
These cuts are destructive because they would be measured in human lives.
With the U.S. as a leading donor, the Global Fund has helped save more than six million lives, and in just a decade has fundamentally altered our ability to fight AIDS, TB, and malaria, among the biggest killers on the planet. If the House proposal to slash $450 million from the Global Fund were adopted it would mean six million treatments for malaria would not be administered. More than 400,000 people won’t be provided with antiretroviral medication to treat AIDS, and nearly 60,000 women won’t receive the drugs they need to prevent transmission of HIV to their newborn children. More than 370,000 people won’t be tested and treated for tuberculosis, the world’s leading curable infectious killer of adults.
This budget crunch comes just as new tools are available to transform the fight against infectious diseases. A new way to diagnosis TB using a machine called Xpert is one such breakthrough. The current method of identifying TB bacteria under a microscope was developed nearly 130 years ago and is still used throughout the developing world. This method often fails to detect TB in people living with HIV/AIDS and in children, cannot detect drug resistance, and is frustratingly slow. Patients must take time off from work and family to return to a clinic and submit multiple specimens over several days — often an impossible demand in very poor communities. Although TB is curable, correctly and rapidly diagnosing the disease has been a major stumbling block.
Xpert has the potential to change that. It’s fast, accurate and easy to use. About the size of an espresso machine, it relies on DNA technology to diagnose TB, detects drug-resistant strains of the disease, and returns the results in about 90 minutes. That may not grab headlines, but in the world of TB control it’s nothing short of revolutionary.
Other breakthroughs abound. The promising trial results for a microbicide gel to prevent HIV transmission electrified the HIV/AIDS community in search of new prevention methods. Vaccines to help prevent pneumonia and diarrhea — the two leading killers of young children — are newly available in poor countries through the GAVI Alliance, an international partnership to expand access to childhood immunizations.
The question for Congress is whether global health policy and funding will keep up with global health evidence and opportunity.
The innovations in global health now at our fingertips are not just new drugs, vaccines, and diagnostics, but also the means of financing and delivering them. For example, The Global Fund to Fight AIDS, Tuberculosis and Malaria has led the way in changing the business model for how aid is delivered. Last week the conservative-led UK government released an exhaustive multilateral aid review of 43 development institutions which rated the Global Fund as one of nine organizations with an “excellent track record” for delivering results. Global Fund proposals are developed by the countries who implement them, they are evaluated by an independent review panel, and continued funding is awarded according to performance. Project documents — everything from glowing reports to unforgiving audits — are made publicly available on the Fund’s website.
That may sound like common sense, but it’s not necessarily common practice among global health and development aid donors.
As a board member of the Global Fund, I see the Fund’s challenges up close, and I also see its ground-breaking model, its impact and the even greater potential it represents. The proven success of the Global Fund allows us to think about seizing the next set of opportunities presented by modern medicine and break the backs of the world’s greatest epidemics.
Congress faces unenviably tough budget decisions this year, but funding for these programs is not a close call. The Senate should reverse the House’s proposed cuts to global health for 2011, and restore this sliver of the federal budget that delivers unparalleled results. To do otherwise would be irrelevant and destructive.
An overweight African rat! This is not a phrase that normally evokes feelings of gratitude, but just waits a minute. African Scientists have reported that rats can save lives by sniffing out tuberculosis with accuracy greater than that of a microscope.
The rat in question is the Gambian pouched rats, which are found in most places in Africa. Researchers are training the rats to be able to smell Mycobacterium tuberculosis, the bacteria that cause TB.
The New York times reports a study conducted in which rats were able to smell the difference between TB bacteria and the other germs found in human sputum sample or phlegm. The rats’ ability to detect TB was as high as 86.6 percent, and their ability to rule it out was over 93 percent!
Most TB tests involve staining a sample of phlegm with a special compound and examining it under a microscope. This 100-year-old method is notoriously unreliable, however — as many as 60 to 80 percent of positive TB cases are undiagnosed, partly because the bacteria are hard to spot unless there are a lot of them in the sample. But the rats were able to sniff them out, detecting 44 percent more positive cases in a head-to-head competition.
Last month, the World Health Organization endorsed a new machine that can provide accurate results within two hours, but it costs $17,000, and each test requires a $17 cartridge. Rats, needless to, come cheap and what a treasure.
Worldwide, TB killed an estimated 1.7 million people in 2009, and 9.4 million people developed active.
The data is still preliminary but encouraging. Eventually, the rats could be used as a first line of detection for the disease
Six in 10 say malaria a very serious problem in Africa
A recent Gallup survey finds that roughly 6 in 10 Americans say malaria is a very serious problem in Africa right now, but they are much more likely to view HIV or AIDS and poor nutrition as very serious problems for that continent. When asked more broadly about the seriousness of malaria worldwide, significantly fewer Americans, only about 3 in 10, consider it a very serious problem, ranking it at the bottom of a list of global health conditions that includes HIV or AIDS, cancer, poor nutrition, and tuberculosis. Democrats are more likely than Republicans to say malaria is a serious health problem in both Africa and around the world more generally.
Overall Results
HIV or AIDS and poor nutrition are, by far, perceived as the most serious health conditions in Africa right now, of the five tested in the poll. Nearly all Americans, 96%, say that HIV or AIDS is a very serious problem in Africa, and 88% say poor nutrition is a very serious problem. A smaller percentage of Americans, but still a majority, say malaria (62%) and tuberculosis (53%) are serious problems facing that continent. Only 30% say cancer is a serious problem in Africa.
On a worldwide basis, at least 8 in 10 Americans say HIV or AIDS, cancer, and poor nutrition are very serious problems around the world right now. Americans perceive tuberculosis and malaria to be less serious problems, with only 31% saying tuberculosis and 28% saying malaria are very serious problems in the world.
The public is almost three times more likely to say cancer is a more serious problem around the world (87%) than it is in Africa (30%). Conversely, Americans perceive malaria (62% vs. 28%) and tuberculosis (53% vs. 31%) to be much more of a problem in Africa than in other parts of the world. Americans are equally likely to say AIDS and poor nutrition are serious problems in the world and in Africa.
While global campaigns are gathering momentum to raise funds for malaria research and prevention, Malian officials have their own plan. Read on.
(AP)
BAMAKO, Mali — The Global Fund to Fight AIDS, Tuberculosis and Malaria said Tuesday that $4 million meant to fight disease in Mali has been misappropriated, prompting them to halt three grants.
The announcement came two days after Malian Health Minister Oumar Ibrahima Toure resigned without explanation on Sunday.
The Global Fund said Tuesday that Malian officials have arrested 15 people suspected of committing fraud; those include several senior health ministry officials.
The international fund said in a statement Tuesday that two malaria grants would be temporarily suspended and a tuberculosis grant would be terminated. Together the grants are worth $22.6 million. The fund has approved some $128 million in assistance for Mali since its creation in 2002. This has come in the form of eight grants – six of them administered by the government.
“The Global Fund tolerates no fraud, and we take public action to stop it, recover lost money and establish new and trustworthy channels for resources so they can reach those in need,” said Michel Kazatchkine, the fund’s executive director
Toure, the health minister, did not respond to requests for comment on Tuesday, nor did Malian government officials. But he had faced several public calls to step down over the Global Fund investigation, and Mali‘s president Amadou Toumani Toure vowed earlier to seek those responsible.
“Whenever someone is accused of wrongdoing, we will do what’s needed so that justice is done,” the president said Saturday. “We must not condemn people too quickly, however. It’s my desire that everyone arrested in connection with this affair has the chance to defend themselves, protect themselves and possibly prove their innocence.”
The fund said the $4 million appeared to have been skimmed through false invoices, fake bid documents and overcharging for goods and services.
The grants provided anti-malarial bed nets, malaria drugs and tuberculosis treatment for prisoners, people in mining communities and patients with multidrug resistant TB.
The fund says the malaria grants will be transferred to another recipient in Mali and treatment will not be interrupted. The tuberculosis patients helped by the other grant will also continue to receive assistance, the fund said.
The poor, landlocked West African nation relies on international donors to fund its health system. In August another international body, the GAVI Alliance, which helps get vaccines to developing countries, also froze the funds it gives to Mali because of corruption fears.